An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth
Open Access
- 17 May 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (11) , 8569-8584
Abstract
The trafficking chaperone PDE6D (or PDEδ) was proposed as a surrogate target for K-Ras, leading to the development of a series of inhibitors that block its prenyl binding pocket. These inhibitors suffered from low solubility and suspected off-target effects, preventing their clinical development. Here, we developed a highly soluble, low nanomolar PDE6D inhibitor (PDE6Di), Deltaflexin3, which has the lowest off-target activity as compared to three prominent reference compounds. Deltaflexin3 reduces Ras signaling and selectively decreases the growth of KRAS mutant and PDE6D-dependent cancer cells. We further show that PKG2-mediated phosphorylation of Ser181 lowers K-Ras binding to PDE6D. Thus, Deltaflexin3 combines with the approved PKG2 activator Sildenafil to more potently inhibit PDE6D/K-Ras binding, cancer cell proliferation, and microtumor growth. As observed previously, inhibition of Ras trafficking, signaling, and cancer cell proliferation remained overall modest. Our results suggest reevaluating PDE6D as a K-Ras surrogate target in cancer.Keywords
All Related Versions
Funding Information
- Fonds National de la Recherche Luxembourg (13589879, PoC20/15269106-inhibitPDE-RASv2)
- Bayer-Stiftungen (2019-08-2426)
This publication has 58 references indexed in Scilit:
- Drug targeting opportunities en route to Ras nanoclusters2022
- Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft modelsActa Pharmaceutica Sinica B, 2021
- FLIM-FRET Analysis of Ras Nanoclustering and Membrane-Anchorage2021
- Development of a PDEδ‐Targeting PROTACs that Impair Lipid MetabolismAngewandte Chemie International Edition, 2019
- PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRasInternational Journal of Cancer, 2018
- A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2Angewandte Chemie International Edition, 2017
- Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding SiteChemistry – A European Journal, 2016
- Combinatorial Assembly of Clone Libraries Using Site-Specific Recombination2013
- A HomozygousPDE6DMutation in Joubert Syndrome Impairs Targeting of Farnesylated INPP5E Protein to the Primary CiliumHuman Mutation, 2013
- Modeling Survival Data: Extending the Cox Model2000